Internal tremors and vibrations in long COVID: a cross-sectional study

Tianna Zhou[1]; Lindsay McAlpine[2]; Teresa Michelsen[3]; César Caraballo[4]; Mitsuaki Sawano[4];

Bornali Bhattacharjee[5,6]; Yuan Lu[4,7]; Akiko Iwasaki[5,6,8]; Harlan M. Krumholz[4,6,7,9*]

1. Yale School of Medicine, New Haven, CT, USA

2. Department of Neurology, Yale School of Medicine, New Haven, CT, USA

3. Avocet Consulting LLC, Hoodsport, WA, USA

4. Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT,

USA

5. Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA

6. Center for Infection and Immunity, Yale School of Medicine, New Haven, CT, USA

7. Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of

Medicine, New Haven, CT, USA

8. Howard Hughes Medical Institute, Chevy Chase, MD, USA

9. Department of Health Policy and Management, Yale School of Public Health, New Haven,

CT, USA

* Corresponding author

Email: harlan.krumholz@yale.edu (HMK)

ABSTRACT

Background: Internal tremors and vibrations symptoms have been described as part of

neurologic disorders but have not been fully described as a part of long COVID. We compared

demographics, socioeconomic characteristics, pre-pandemic comorbidities, and new-onset

conditions between people with internal tremors and vibrations as part of their long COVID

symptoms and people with long COVID but without these symptoms.

Methods: A cross-sectional study, Listen to Immune, Symptom and Treatment Experiences Now

(LISTEN), collected data from adults with long COVID. The study sample included 423

participants enrolled between May 2022 and June 2023.

Results: The 423 participants had a median age of 46 years (interquartile range, 38-56), 74%

were female, 87% were Non-Hispanic White, and 158 (37%) reported "internal tremors, or

buzzing/vibration" as a long COVID symptom. Before long COVID, the groups had similar

comorbidities. Post-COVID, participants with internal tremors and vibrations had significantly

worse health as measured by the Euro-QoL visual analogue scale (median: 40 vs. 50 points, P =

0.007), higher rates of financial difficulties caused by the pandemic and housing insecurity (P <

0.001 for each), and were significantly more likely to have new-onset conditions of mast cell

disorders (11% vs. 2.6%), neurologic conditions (22% vs. 8.3%), anxiety (20% vs. 8.7%), and

trauma- or stress-related mental health disorders (12% vs. 3.4%) compared with those without

internal tremors (Bonferroni-adjusted P < 0.05 for each). Participants with internal tremors also

reported significantly higher rates of cardiovascular, gastrointestinal, integumentary, and

neurologic long COVID symptoms compared with those without internal tremors (Bonferroni-

adjusted P < 0.05 for each).

Conclusions and Relevance: Among people with long COVID, those with internal tremors and

vibrations have more associated symptoms and worse health status, suggesting it may be

associated with a severe phenotype of the condition.

INTRODUCTION

Internal tremors and vibrations are an understudied symptom, despite their first written

descriptions by a patient in the 1800s.[1] Internal tremors were described as a movement or

sensation of movement at any location inside the body. They can occur either with or without

visible external movement or muscle spasms.[2, 3] Until recently, internal tremors have been

described mostly among patients with Parkinson's disease and essential tremor.[1-6] In those

populations, internal tremors have been associated with anxiety and sensory abnormalities such

as aching, tingling, and burning.[5] In a recent qualitative study, we described long COVID

symptoms of internal tremors and vibrations and their substantial and negative impact on

people's quality of life.[2]

Here, we compared the demographics, socioeconomic characteristics, pre-pandemic

comorbidities, and new-onset conditions between people with long COVID symptoms of internal

tremors and vibrations and others with long COVID. To the best of our knowledge, to date, no

quantitative study has described long COVID symptoms of internal tremors and vibrations.

Throughout this paper, terminology and definitions were deliberately chosen to respect

participants' epistemic authority. For example, long COVID was defined by participants' self-

report rather than definitions proposed by public health and medical organizations.[7] Similarly,

this paper used the term "internal tremors," a shortened phrase to denote "internal tremors and

vibrations," which reflects the language used by participants to describe their symptom

experience. Internal tremors were considered to be different from tremors, which were defined

by expert consensus as "involuntary, rhythmic, oscillatory movement of a body part."[8] In this

paper's context, internal tremors were considered a participant-reported symptom rather than a

clinician-observed sign.[9]

METHODS

Study design

We used data from the long COVID component of the Listen to Immune, Symptom, and

Treatment Experiences Now (LISTEN) Study, an online, decentralized, participant-centric,

observational study of adults interested in contributing to COVID-related research. The LISTEN

Study included two parts: survey and electronic health record data collection and analysis to

characterize clinical phenotypes and biospecimen collection for immunophenotyping. This study

focused on survey data only.

Study sample

LISTEN recruited from people who joined Hugo Health Kindred, an online platform of

individuals 18 years and older who were interested in contributing to COVID-related research.

The objective was to include people with long COVID, vaccine-associated adverse events, and

those who could act as controls; this study focused on people with long COVID. People joined

Hugo Health Kindred by word of mouth, including via social media. Additionally, a subset of

active Kindred members was invited to join a Kindred Advisory Task Force to help recruit others

by sharing information about Kindred. Eligibility criteria to join LISTEN were 1) age 18 years or

older and 2) English speaking.

Data collection

Those who joined Kindred were offered a series of surveys developed in an iterative

process that included input from people with long COVID and those with vaccine-associated

adverse events. Surveys were available for completion online on computers or mobile devices.

Participants were sent electronic reminders to encourage survey completion. The data became

part of each person's data repository, available to be shared with research studies. People in

Kindred were offered the opportunity to join LISTEN; e-consent was performed online.

This study was restricted to people who joined LISTEN and had completed their

demographic and conditions and symptoms surveys. Participants with long COVID were

identified as those who replied "yes" to the question, "Do you think you have long COVID?"

Demographic and socioeconomic survey items included age, gender, race and ethnicity,

marital status, pre-pandemic employment and income, housing insecurity, and country of

residence. Self-reported time of index SARS-CoV-2 infection was categorized as Pre-Delta

(before 26 June 2021), Delta (26 June 2021–24 December 2021), Omicron (25 December 2021–

25 June 2022), and Post-Omicron (after 25 June 2022), consistent with time period definitions

associated with dominant variants of SARS-CoV-2.[10] SARS-CoV-2 infection severity was

assessed by self-reported hospitalization history for COVID-related conditions.

The demographic survey included two questions about health status; self-reported health

status was assessed by the Euro-QoL visual analogue scale (EQ-VAS), and the question, "We are

trying to get a sense of how bad your long COVID symptoms are when you feel them the most.

On the slider below, with 0 being a trivial illness and 100 being unbearable, please let us know

what the worst days are like." (S1 Methods - Health status questions).[11]

The conditions and symptoms survey assessed pre-pandemic comorbidities, current

conditions, and long COVID symptoms. Pre-pandemic comorbidities were assessed using the

question, "Have you ever been told by a doctor before January 2020 that you have any of the

following?" followed by a list of 30 medical diagnostic categories, 8 psychiatric diagnostic

categories, "other," and "none of the above" (S2 Methods – Pre-pandemic comorbidities

questions). Current conditions were assessed using the question, "Currently, have you ever been

told by a doctor that you have any of the following?" followed by a list of 31 medical diagnostic

categories, 8 psychiatric diagnostic categories, "other," and "none of the above" (S2 Methods -

Current conditions questions). For each participant, we defined new-onset conditions as those

reported as a current condition but not reported as a pre-pandemic comorbidity.

Long COVID symptoms were assessed by the question, "Please select all following

health conditions that you have had as a result of long COVID," followed by a list of 95 specific

symptoms, "other," and "none of the above" (S3 Methods - Long COVID symptoms questions).

All phrasings of symptoms on the multiple-choice list were created in collaboration with

participants and were reported in this study's tables as they appeared on the survey. We excluded

the fatigue symptom and runny nose symptom variables from analysis due to their overlap with

the excessive fatigue symptom and congested or runny nose symptom.

After exclusion for incomplete conditions and symptoms surveys, the study sample

represented 69% of participants enrolled in LISTEN who completed the demographic survey and

reported long COVID and no vaccine-associated adverse events.

Statistical analysis

We described participant characteristics using percentages for categorical variables, and

median and interquartile range (IQR) for continuous variables. We compared participants with

and without internal tremors on their demographic and socioeconomic characteristics, medical

conditions, and long COVID symptoms. We used chi-squared tests and Fisher's exact tests to

compare responses for categorical variables and Wilcoxon rank-sum tests and Kruskal-Wallis

rank-sum tests for continuous variables. When comparing the three domains of pre-pandemic

comorbidities, new-onset conditions, and long COVID symptoms between the two groups, we

corrected for multiple testing using the Bonferroni method within each domain and reported

adjusted P-values. All tests were two-sided. P < 0 .05 was considered statistically significant. By

using the Bonferroni method, family-wise error rates were controlled at the level of 0.05. All

statistical analyses were done in R version 4.2.3 (2023-03-15).

Ethical considerations

The LISTEN study was approved by the Yale University Institutional Review Board on

April 1, 2022. Participants were provided electronic written consent forms. LISTEN conforms to

the Declaration of Helsinki and STROBE reporting guidelines.

RESULTS

From 7 May 2022 to 1 June 2023, 614 people with long COVID consented to and

enrolled in LISTEN and completed the demographic survey (Figure 1). Among them, 191

participants (31%) were excluded due to incomplete conditions and symptoms surveys, leaving

423 participants (69%) in the study population (Figure 1). The included participants were

significantly older (median: 46 years vs. 43 years, P = 0.014) compared with those who were

excluded from the analysis (S1 Table). The participants were similar in gender, race and

ethnicity, country of residence, and EQ-VAS health status.

Demographic and pre-pandemic socioeconomic characteristics

Among participants with long COVID, median age was 46 years (IQR, 38-56), 74% were

female, 87% were Non-Hispanic White, and 158 participants (37%) reported internal tremors

(Table 1). Compared with participants without internal tremors, those with internal tremors were

more likely to be female (81% vs. 70%, P = 0.018). The two groups had no significant

differences in age, race and ethnicity, marital status, pre-pandemic employment status, and pre-

pandemic household income (P > 0.05).

Pre-pandemic comorbidities

Overall, among participants, the most common self-reported pre-pandemic comorbidities

were anxiety disorders (30%), depressive disorders (29%), and gastrointestinal issues, including

irritable bowel syndrome and acid reflux (24%). After adjusting for multiple testing, participants

with and without internal tremors were not significantly different in any self-reported pre-

pandemic comorbidities (adjusted $P > 0.05$ for each; S2 Table).

SARS-CoV-2 infection characteristics and post-COVID socioeconomic characteristics

Overall, the most common period for index SARS-CoV-2 infection was during the Pre-

Delta wave (46%) and 9.5% of participants were hospitalized due to COVID-related conditions

(Table 2, S1 Figure). Participants with internal tremors were significantly more likely to report

their index infection during the Pre-Delta wave (53% vs. 42%, $P = 0.006$) but were not

significantly different in hospitalization rates due to COVID-related conditions. Participants with

internal tremors had a significantly longer duration between their initial infections and the date of

completing LISTEN's symptom survey (median: 74 weeks vs. 54 weeks, $P = 0.003$).

Participants with and without internal tremors had no significant differences in their

health insurance status and level of social support when completing the surveys ($P > 0.05$; Table

2). Participants with internal tremors were significantly more likely to report having financial

difficulties caused by the pandemic (very much financial difficulties, 22% vs. 11%, $P < 0.001$),

often feeling socially isolated (43% vs. 37%, $P = 0.039$), and housing insecurity (worried about

losing housing, 18% vs. 8.3%, $P < 0.001$).

Health status

Participants with internal tremors reported significantly worse health as measured by EQ-

VAS, using a visual sliding scale ranging from 0 to 100, where 0 means the worst and 100 means

the best (median: 40 points [IQR, 30-60] vs. 50 points [IQR, 35-62], P = 0.007) compared with

those with no internal tremors (Table 3, Figure 2). When asked to rate their symptom severity on

their worst days using a visual sliding scale ranging from 0 to 100, with 0 being a trivial illness

and 100 being unbearable, participants with internal tremors reported greater symptom severity

compared with those with no internal tremors (median: 80 points [IQR 73–90] vs. 73 points

[IQR, 60–82], respectively, P < 0.001; Table 3, Figure 3). In both groups, the time period of the

index SARS-CoV-2 infection was not significantly associated with EQ-VAS scores (S3 Table).

New-onset conditions

Overall, the most common new-onset conditions among all participants were postural

orthostatic tachycardia syndrome or other dysautonomia (25%), gastrointestinal issues (15%),

and neurologic conditions (13%) (S4 Table). Compared with participants without internal

tremors, significantly greater proportions of participants with internal tremors reported new-

onset mast cell disorders (11% vs. 2.6%, adjusted P = 0.008), neurologic conditions (22% vs.

8.3%, adjusted P = 0.004), anxiety disorders (20% vs. 8.7%, adjusted P = 0.038), and trauma-

and stressor-related disorders (12% vs. 3.4%, adjusted P = 0.019; Figure 2, S4 Table).

Long COVID symptoms

Overall, the most common long COVID symptoms reported were excessive fatigue

(87%), brain fog (86%), exercise intolerance (79%), trouble falling or staying asleep (72%), and

memory problems (70%) (S5 Table). Among participants with internal tremors, the most

common symptoms appeared to affect constitutional, neurological, and cardiovascular systems.

For constitutional and generalized symptoms, from most common to least common,

participants with internal tremors had significantly higher rates of trouble falling or staying

asleep (84% vs. 65%), dizziness (75% vs. 49%), muscle or body aches (70% vs. 49%), heat

intolerance (61% vs. 38%), night sweats (54% vs. 34%), chills but no fever (49% vs. 26%),

constant thirst (41% vs. 17%), feelings of impending doom (35% vs. 19%), nightmares (26% vs.

12%), abnormally low temperature (22% vs. 7.5%), and fainting (19% vs. 4.9%) compared with

those without internal tremors (adjusted P < 0.05 for each; S5 Table). Rates of exercise

intolerance and excessive fatigue did not differ significantly between the two groups (adjusted

P > 0.05 for each).

For neurological symptoms, from most common to least common, participants with

internal tremors were more likely to have headaches (77% vs. 56%), tingling, pins and needles,

or numbness (72% vs. 41%), tremors or shakiness (65% vs. 22%), neuropathy (nerve sensations

including pain) anywhere in the body (64% vs. 34%), pressure at the base of the head (51% vs.

27%), burning sensations (42% vs. 19%), migraines (42% vs. 23%), and painful scalp (25% vs.

8.7%) compared with those with no internal tremors (adjusted P < 0.05 for each; S5 Table).

Participants with internal tremors were also more likely to have auditory, visual, and olfactory

symptoms such as tinnitus (62% vs. 36%), loss or decrease in quality of vision/blurry vision

(54% vs. 34%), floaters or flashes of light in vision (47% vs. 16%), changed sense of smell (42%

vs. 25%), and phantom smells (35% vs. 16%) compared with those without internal tremors

(adjusted P < 0.05 for each). The two groups were not significantly different in rates of

confusion, brain fog, memory problems, difficulty speaking, seizures, loss of hearing, and

gustatory symptoms (adjusted P > 0.05 for each).

For cardiovascular and thoracic symptoms, from most common to least common,

participants with internal tremors were more likely to have palpitations (66% vs. 44%),

tachycardia after standing up (58% vs. 39%) or at rest (57% vs. 34%), sharp or sudden chest pain

(47% vs. 22%), persistent chest pain or pressure (44% vs. 26%), costochondritis (37% vs. 18%),

and bilateral neck throbbing (23% vs. 7.5%) compared with those without internal tremors

(adjusted P < 0.05 for each; S5 Table). The two groups were not significantly different in rates of

pulmonary symptoms such as cough, wheezing, and shortness of breath (adjusted P > 0.05 for

each).

234   Participants with internal tremors were more likely to have integumentary symptoms

235   such as hair loss (56% vs. 30%), itchiness (39% vs. 17%), skin bruising (32% vs. 16%), change

236   in nails (30% vs. 13%), discoloration of the skin (29% vs. 11%), cracked or dry lips (28% vs.

237   13%), tender or itchy rash or chilblains on the toes or foot (15% vs. 1.9%), and chilblains on the

238   hands or feet (11% vs. 2.3%) compared with those with no internal tremors (adjusted P < 0.05

239   for each; S5 Table).

240   For gastrointestinal symptoms, participants with internal tremors were more likely to

have abdominal pain (47% vs. 23%), diarrhea (43% vs. 24%), loss of appetite (41% vs. 24%),

throat pain or discomfort (34% vs. 16%), inability to eat or tolerate food (32% vs. 15%),

difficulty swallowing (27% vs. 12%), and lump in throat (22% vs. 9.1%) compared with those

with no internal tremors (adjusted P < 0.05 for all; S5 Table). The two groups were not

significantly different in rates of other gastrointestinal symptoms such as acid reflux/heartburn,

constipation, and nausea/vomiting (adjusted P > 0.05 for each).

DISCUSSION

249   In a cross-sectional sample of people with long COVID, we found internal tremors were

a common symptom, affecting 37% of participants. Participants with internal tremors were like

those without internal tremors in their demographic characteristics. Importantly, although the

two groups had similar pre-pandemic comorbidities, participants with internal tremors had worse

EQ-VAS health status and higher rates of financial difficulties caused by the pandemic and

housing insecurity compared with those without internal tremors. Participants with internal

tremors reported significantly higher rates of new-onset conditions for mast cell disorders,

neurologic disorders, anxiety disorders, and trauma- and stress-related disorders. Participants

with internal tremors also reported significantly higher rates of cardiovascular, neurologic,

gastrointestinal, and integumentary long COVID symptoms.

To the best of our knowledge, only four prior studies have described patients with

internal tremors;[3-5, 12] no quantitative study of patients with long COVID has fully described

symptoms of internal tremors. A prior study of patients with Parkinson's disease found that

internal tremors were associated with anxiety and sensory symptoms such as aching, tingling,

and burning.[5] Sensory abnormalities have also been described in long COVID cohorts,[13] as well

as in the subset of people with post-COVID onset of neuropathies[14], such as small fiber

neuropathy.[15, 16] These prior long COVID studies described sensory symptoms such as burning,

tingling, and numbness, but did not explicitly describe internal tremors and vibrations. Two

recent studies based on large prospective cohorts of people with long COVID did not report on

symptoms of internal tremors.[10, 17] Our study adds to prior findings by showing that compared

with others with long COVID, participants with internal tremors had significantly higher rates of

sensory abnormalities such as neuropathy sensations, olfactory changes, and tinnitus.

Prior studies also noted associations among dysautonomia, long COVID, and small fiber

neuropathy.[16, 18] Compared with participants with no internal tremors, those with internal tremors

reported significantly higher rates of symptoms across multiple autonomic domains, including

orthostatic symptoms (tachycardia, dizziness, fainting, and weakened neck, which may resemble

coat hanger syndrome[19]), vasomotor symptoms (skin discoloration), secretomotor (night sweats,

dry eyes), and symptoms related to slow or fast gastrointestinal transit (difficulty swallowing,

diarrhea).[19-21] Rates of new-onset dysautonomia were higher among participants with internal

tremors, with statistical significance before but not after Bonferroni correction. The mechanism

of dysautonomia among patients with Parkinson's disease may be related to organ-selective

sympathetic denervation,[22] but the pathophysiologic links among dysautonomia, long COVID,

and internal tremors have not been established and should be explored in further studies.

In this study, participants with internal tremors had new-onset mast cell disorders at a

significantly higher rate compared with participants with long COVID but no internal tremors.

Mast cells form neuroimmune synapses with peripheral nerves and serve both an afferent role to

modulate neural function, as well as an efferent role in neurogenic inflammation.[23] Mast cell

activation symptoms have been documented among long COVID patients [24] and patients with

small fiber neuropathy.[25] Further studies will be needed to elucidate the underlying

pathophysiologic link and determine if any subset of long COVID conditions and mast cell

disorders are causally related.

Our findings add nuance to the hypothesized associations between myalgic

encephalomyelitis/chronic fatigue syndrome and long COVID, which are often discussed

together due to overlapping symptomatology and infectious etiopathogenesis.[26-28] Although

greater than 70% of all subgroups in this study reported excessive fatigue and exercise

intolerance, these hallmark symptoms of myalgic encephalomyelitis/chronic fatigue syndrome

were not significantly associated with internal tremors. Our findings are consistent with prior

observations of long COVID as a heterogeneous condition with many phenotypes,[29] which may

be driven by several mechanisms.[30]

Study limitations

This study has several limitations. The study sample was recruited from an online long

COVID community and should not be considered representative. Rather, the study provides an

opportunity to describe the characteristics of people within the online community who do and do

not have internal tremors and vibrations. In this study, 31% of enrolled participants with long

COVID did not complete their conditions and symptoms surveys. The effort required to

complete surveys may preclude those with low functional status from participation. However,

participants included and excluded based on symptom survey completion were similar in their

low median EQ-VAS score. In addition, conditions and symptoms are based on self-reporting

using a pre-specified checklist, which may be susceptible to recall bias with unclear

directionality for under versus overreporting, as well as inaccuracies such as misdiagnoses due to

uncertainties surrounding long COVID evaluation and management during early stages of the

pandemic.

<u>Conclusions</u>

Internal tremors and vibrations are common symptoms among people with long COVID.

People with these symptoms had pre-infection characteristics similar to those of others with long

COVID, but compared with others who had long COVID, they had worse EQ-VAS health status

and higher rates of financial difficulties and housing insecurity, and higher self-reported rates of

new-onset conditions of mast cell disorders, neurologic conditions, anxiety, and trauma- and

stressor-related conditions. Individuals with long COVID symptoms of internal tremors may

experience a particularly severe phenotype of long COVID. Clinicians should be aware of

internal tremors and vibrations as a long COVID symptom. Further research is needed to clarify

the pathophysiology of internal tremors and vibrations and identify potential treatment targets.

ACKNOWLEDGMENTS

We thank Shaun Barcavage, FNP-BC, James Curry, MD, and Kelley Royer, RN for their

feedback and for sharing their lived experiences with the writing team, and Maria Johnson for

her editorial contributions.

FUNDING

This study was in part funded by the Howard Hughes Medical Institute Collaborative COVID-19

Initiative, and grants from the National Institute of Allergy and Infectious Diseases

(R01AI157488 to Akiko Iwasaki).

CONFLICTS OF INTEREST

Harlan Krumholz and his spouse are co-founders of, and have equity in, Hugo Health, the

personalized health data-platform company that developed the Hugo Kindred platform. Dr.

Krumholz is a scientific advisor to, and his spouse is an officer with, Hugo Health. His

involvement in this study is overseen by the Yale Conflict of Interest Committee. In the past

three years, Harlan Krumholz received expenses and/or personal fees from UnitedHealth,

Element Science, Eyedentifeye, and F-Prime. He is a co-founder of Refactor Health and is

associated with contracts, through Yale New Haven Hospital, from the Centers for Medicare &

Medicaid Services and through Yale University from the Food and Drug Administration,

Johnson & Johnson, Google, and Pfizer.

REFERENCES

1.   Horowski R, Horowski L, Vogel S, Poewe W, Kielhorn FW. An essay on Wilhelm von Humboldt and the shaking palsy: first comprehensive description of Parkinson's disease by a patient. *Neurology*. Mar 1995;45(3 Pt 1):565-8. doi:10.1212/wnl.45.3.565

2.   Massey D, Baker AD, Berrent DZ, et al. Internal tremors and vibration symptoms among people with post-acute sequelae of SARS-CoV-2: a narrative review of patient reports. *medRxiv*. 2021:2021.12.03.21267146. doi:10.1101/2021.12.03.21267146

3.   Cochrane GD, Rizvi S, Abrantes A, Crabtree B, Cahill J, Friedman JH. Internal tremor in Parkinson's disease, multiple sclerosis, and essential tremor. *Parkinsonism Relat Disord*. Oct 2015;21(10):1145-7. doi:10.1016/j.parkreldis.2015.07.014

4.   Raudino F. Non motor off in Parkinson's disease. *Acta Neurol Scand*. Nov 2001;104(5):312-5. doi:10.1034/j.1600-0404.2001.00357.x

5.   Shulman LM, Singer C, Bean JA, Weiner WJ. Internal tremor in patients with Parkinson's disease. *Mov Disord*. Jan 1996;11(1):3-7. doi:10.1002/mds.870110103

6.   Friedman JH. Non-motor movement disorders: internal tremor. *Med Health R I*. Aug 2009;92(8):262.

7.   Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. *Lancet Infect Dis*. Apr 2022;22(4):e102-e107. doi:10.1016/S1473-3099(21)00703-9

8.   Bhatia KP, Bain P, Bajaj N, et al. Consensus statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. *Mov Disord*. Jan 2018;33(1):75-87. doi:10.1002/mds.27121

9.   Louis ED, Bain PG. Problems and controversies in tremor classification. *J Neurol Sci*. Apr 15 2022;435:120204. doi:10.1016/j.jns.2022.120204

10.   Gottlieb M, Wang R, Yu H, et al. Severe fatigue and persistent symptoms at three months following SARS-CoV-2 infections during the Pre-Delta, Delta, and Omicron time periods: a multicenter prospective cohort study. *Clin Infect Dis*. Jan 27 2023;doi:10.1093/cid/ciad045

11.   Rabin R, de Charro F. EQ-SD: a measure of health status from the EuroQol Group. *Annals of Medicine*. 2001/01/01 2001;33(5):337-343. doi:10.3109/07853890109002087

12.   Borromei A, Caramelli R, Battistelli P, D'Orsi U, Pasini W, Vargiu B. 5-30-01 Internal tremor: a clinical marker for the onset of Parkinson's disease? *Journal of the Neurological Sciences*. Sep 1997;150:S315. doi:10.1016/S0022-510X(97)86438-6

13.   Writing Committee for the COMEBAC Study Group, Morin L, Savale L, et al. Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. *JAMA*. Apr 20 2021;325(15):1525-1534. doi:10.1001/jama.2021.3331

14.   Oaklander AL, Mills AJ, Kelley M, et al. Peripheral neuropathy evaluations of patients with prolonged long COVID. *Neurol Neuroimmunol Neuroinflamm*. May 2022;9(3)doi:10.1212/NXI.0000000000001146

15.   Abrams RMC, Simpson DM, Navis A, Jette N, Zhou L, Shin SC. Small fiber neuropathy associated with SARS-CoV-2 infection. *Muscle Nerve*. Apr 2022;65(4):440-443. doi:10.1002/mus.27458

16.   Novak P, Giannetti MP, Weller E, et al. Network autonomic analysis of post-acute sequelae of COVID-19 and postural tachycardia syndrome. *Neurol Sci*. Dec 2022;43(12):6627-6638. doi:10.1007/s10072-022-06423-y

17.   Thaweethai T, Jolley SE, Karlson EW, et al. Development of a Definition of Postacute
Sequelae of SARS-CoV-2 Infection. *JAMA*. 2023;329(22):1934-1946.
doi:10.1001/jama.2023.8823
18.   Shoenfeld Y, Ryabkova VA, Scheibenbogen C, et al. Complex syndromes of chronic
pain, fatigue and cognitive impairment linked to autoimmune dysautonomia and small fiber
neuropathy. *Clin Immunol*. May 2020;214:108384. doi:10.1016/j.clim.2020.108384
19.   Goldstein DS, Cheshire WP, Jr. The autonomic medical history. *Clin Auton Res*. Aug
2017;27(4):223-233. doi:10.1007/s10286-017-0425-7
20.   Kim MJ, Farrell J. Orthostatic hypotension: a practical approach. *Am Fam Physician*. Jan
1 2022;105(1):39-49.
21.   Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. COMPASS 31: a refined and
abbreviated Composite Autonomic Symptom Score. *Mayo Clin Proc*. Dec 2012;87(12):1196-
201. doi:10.1016/j.mayocp.2012.10.013
22.   Goldstein DS. Dysautonomia in Parkinson disease. *Compr Physiol*. Apr 2014;4(2):805-
26. doi:10.1002/cphy.c130026
23.   Forsythe P. Mast cells in neuroimmune interactions. *Trends Neurosci*. Jan 2019;42(1):43-
55. doi:10.1016/j.tins.2018.09.006
24.   Weinstock LB, Brook JB, Walters AS, Goris A, Afrin LB, Molderings GJ. Mast cell
activation symptoms are prevalent in Long-COVID. *Int J Infect Dis*. Nov 2021;112:217-226.
doi:10.1016/j.ijid.2021.09.043
25.   Novak P, Giannetti MP, Weller E, Hamilton MJ, Castells M. Mast cell disorders are
associated with decreased cerebral blood flow and small fiber neuropathy. *Ann Allergy Asthma*
Immunol. Mar 2022;128(3):299-306 e1. doi:10.1016/j.anai.2021.10.006
26.   Wong TL, Weitzer DJ. Long COVID and myalgic encephalomyelitis/chronic fatigue
syndrome (ME/CFS)-a Systemic review and comparison of clinical presentation and
symptomatology. *Medicina (Kaunas)*. Apr 26 2021;57(5)doi:10.3390/medicina57050418
27.   Retornaz F, Rebaudet S, Stavris C, Jammes Y. Long-term neuromuscular consequences
of SARS-Cov-2 and their similarities with myalgic encephalomyelitis/chronic fatigue syndrome:
results of the retrospective CoLGEM study. *J Transl Med*. Sep 24 2022;20(1):429.
doi:10.1186/s12967-022-03638-7
28.   Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes.
Nat Med. May 2022;28(5):911-923. doi:10.1038/s41591-022-01810-6
29.   Zhang H, Zang C, Xu Z, et al. Data-driven identification of post-acute SARS-CoV-2
infection subphenotypes. *Nat Med*. Jan 2023;29(1):226-235. doi:10.1038/s41591-022-02116-3
30.   Castanares-Zapatero D, Chalon P, Kohn L, et al. Pathophysiology and mechanism of long
COVID: a comprehensive review. *Ann Med*. Dec 2022;54(1):1473-1487.
doi:10.1080/07853890.2022.2076901
423

425 **TABLES AND FIGURES**
426 Figure 1. Sample selection

427
428 LISTEN, Listen to Immune, Symptom and Treatment Experiences Now
429
430

431   Figure 2. Distribution of health status, measured by the Euro-QoL visual analogue scale

432
433   Assessed by the question, "Please choose one point in this 0-100 scale, which can best represent
434   your health today (0 means the worst and 100 means the best)." (S1 Methods - Health status
435   questions)
436

437   Figure 3. Distribution of symptom severity

438
439   Assessed by the question, "We are trying to get a sense of how bad your long COVID symptoms
440   are when you feel them the most. On the slider below, with 0 being a trivial illness and 100 being
441   unbearable, please let us know what the worst days are like." (S1 Methods - Health status
442   questions)
443
444

445   Figure 4. New-onset conditions

446
447
448   * Bonferroni adjusted p < 0.05
449   ** Bonferroni adjusted p < 0.01
450
451   Abbreviations: MCAS, mast cell activation syndrome; ME/CFS, myalgic
452   encephalomyelitis/chronic fatigue syndrome; POTS, postural orthostatic tachycardia syndrome

453   Table 1. Participant demographics and pre-pandemic socioeconomic characteristics

	Overall, N = 423	**No internal tremors**, N = 265	**Has internal tremors**, N = 158	**p-value**[1]
	n/N, % [95% CI]	**n/N, % [95% CI]**	**n/N, % [95% CI]**	
Age (years), median, IQR	46, 38-56	46, 39-58	46, 38-53	0.225
Gender				0.018
Female	313/423, 74% [69-78%]	185/265, 70% [64-75%]	128/158, 81% [74-87%]	
Male	108/423, 26% [21-30%]	78/265, 29% [24-35%]	30/158, 19% [13-26%]	
Non-binary	2/423, 0.5% [0.08-1.9%]	2/265, 0.8% [0.13-3.0%]	0/158, 0% [0.00-3.0%]	
Race and ethnicity				0.458
Asian	11/423, 2.6% [1.4-4.7%]	9/265, 3.4% [1.7-6.6%]	2/158, 1.3% [0.22-5.0%]	
Black	8/423, 1.9% [0.88-3.8%]	6/265, 2.3% [0.92-5.1%]	2/158, 1.3% [0.22-5.0%]	
Latino	15/423, 3.5% [2.1-5.9%]	7/265, 2.6% [1.2-5.6%]	8/158, 5.1% [2.4-10%]	
Multiracial or Other	21/423, 5.0% [3.2-7.6%]	13/265, 4.9% [2.7-8.4%]	8/158, 5.1% [2.4-10%]	
Non-Hispanic White	368/423, 87% [83-90%]	230/265, 87% [82-91%]	138/158, 87% [81-92%]	
Country of residence				0.807
Canada	11/423, 2.6% [1.4-4.7%]	7/265, 2.6% [1.2-5.6%]	4/158, 2.5% [0.81-6.8%]	
Germany	5/423, 1.2% [0.44-2.9%]	2/265, 0.8% [0.13-3.0%]	3/158, 1.9% [0.49-5.9%]	
United Kingdom	5/423, 1.2% [0.44-2.9%]	3/265, 1.1% [0.29-3.5%]	2/158, 1.3% [0.22-5.0%]	

U.S.	391/423, 92% [89-95%]	247/265, 93% [89-96%]	144/158, 91% [85-95%]	
Other countries	11/423, 2.6% [1.4-4.7%]	6/265, 2.3% [0.92-5.1%]	5/158, 3.2% [1.2-7.6%]	
Marital status				0.956
Divorced	42/398, 11% [7.8-14%]	27/253, 11% [7.3-15%]	15/145, 10% [6.1-17%]	
Married or civil union	237/398, 60% [55-64%]	151/253, 60% [53-66%]	86/145, 59% [51-67%]	
Never married	109/398, 27% [23-32%]	69/253, 27% [22-33%]	40/145, 28% [21-36%]	
Separated	6/398, 1.5% [0.61-3.4%]	3/253, 1.2% [0.31-3.7%]	3/145, 2.1% [0.54-6.4%]	
Widowed	4/398, 1.0% [0.32-2.7%]	3/253, 1.2% [0.31-3.7%]	1/145, 0.7% [0.04-4.4%]	
Missing data	25	12	13	
Employed pre-pandemic	338/396, 85% [81-89%]	213/252, 85% [79-89%]	125/144, 87% [80-92%]	0.537
Missing data	27	13	14	
Pre-pandemic annual household income				0.677
$10,000 to $35,000	20/396, 5.1% [3.2-7.8%]	12/252, 4.8% [2.6-8.4%]	8/144, 5.6% [2.6-11%]	
$35,000 to less than $50,000	29/396, 7.3% [5.0-10%]	15/252, 6.0% [3.5-9.8%]	14/144, 9.7% [5.6-16%]	
$50,000 to less than $75,000	38/396, 9.6% [7.0-13%]	25/252, 9.9% [6.6-14%]	13/144, 9.0% [5.1-15%]	
$75,000 or more	274/396, 69% [64-74%]	176/252, 70% [64-75%]	98/144, 68% [60-75%]	
Less than $10,000	4/396, 1.0% [0.32-2.7%]	2/252, 0.8% [0.14-3.1%]	2/144, 1.4% [0.24-5.4%]	

Prefer not to answer	31/396, 7.8% [5.5-11%]	22/252, 8.7% [5.7-13%]	9/144, 6.2% [3.1-12%]	
Missing data	27	13	14	
[1] Wilcoxon rank sum test; Fisher's exact test; Pearson's Chi-squared test				

455   Table 2. SARS-CoV-2 infection and post-COVID socioeconomic characteristics
456

	Overall, N = 423	**No internal tremors**, N = 265	**Has internal tremors**, N = 158	**p-value**[1]
	n/N, % [95% CI]	**n/N, % [95% CI]**	**n/N, % [95% CI]**	
Index SARS-CoV-2 infection time period				0.006
Pre-Delta	171/373, 46% [41-51%]	97/233, 42% [35-48%]	74/140, 53% [44-61%]	
Delta	48/373, 13% [9.7-17%]	27/233, 12% [7.9-17%]	21/140, 15% [9.7-22%]	
Omicron	110/373, 29% [25-34%]	72/233, 31% [25-37%]	38/140, 27% [20-35%]	
Post-Omicron	44/373, 12% [8.8-16%]	37/233, 16% [12-21%]	7/140, 5.0% [2.2-10%]	
Missing data	50	32	18	
Hospitalized for COVID-related conditions	40/423, 9.5% [6.9-13%]	20/265, 7.5% [4.8-12%]	20/158, 13% [8.1-19%]	0.082
Number of weeks between infection and taking the symptom survey	63, 32-111	54, 26-99 [59-71]	74, 38-118 [71-86]	0.003
Missing data	50	32	18	
Financial difficulties caused by the pandemic				<0.001
Not at all	125/396, 32% [27-36%]	94/252, 37% [31-44%]	31/144, 22% [15-29%]	
A little	146/396, 37% [32-42%]	95/252, 38% [32-44%]	51/144, 35% [28-44%]	
Quite a bit	66/396, 17% [13-21%]	36/252, 14% [10-19%]	30/144, 21% [15-29%]	

Very much	59/396, 15% [12-19%]	27/252, 11% [7.3-15%]	32/144, 22% [16-30%]	
Missing data	27	13	14	
Do not have health insurance	15/423, 3.5% [2.1-5.9%]	9/265, 3.4% [1.7-6.6%]	6/158, 3.8% [1.6-8.5%]	0.829
Social support (someone around to help you if you need it)				0.766
Never	24/398, 6.0% [4.0-9.0%]	16/253, 6.3% [3.8-10%]	8/145, 5.5% [2.6-11%]	
Rarely	31/398, 7.8% [5.4-11%]	22/253, 8.7% [5.7-13%]	9/145, 6.2% [3.1-12%]	
Sometimes	72/398, 18% [15-22%]	42/253, 17% [12-22%]	30/145, 21% [15-28%]	
Usually	148/398, 37% [32-42%]	93/253, 37% [31-43%]	55/145, 38% [30-46%]	
Always	123/398, 31% [26-36%]	80/253, 32% [26-38%]	43/145, 30% [23-38%]	
Missing data	25	12	13	
Social isolation (how often do you feel isolated from others?)				0.039
Hardly ever or never	85/395, 22% [18-26%]	64/251, 25% [20-31%]	21/144, 15% [9.5-22%]	
Some of the time	155/395, 39% [34-44%]	94/251, 37% [32-44%]	61/144, 42% [34-51%]	
Often	155/395, 39% [34-44%]	93/251, 37% [31-43%]	62/144, 43% [35-52%]	
Missing data	28	14	14	
Housing				<0.001
I do not have a steady place to live	4/398, 1.0% [0.32-2.7%]	0/253, 0% [0.00-1.9%]	4/145, 2.8% [0.89-7.4%]	

I have a place to live today, but I am worried about losing it in the future	47/398, 12% [8.9-15%]	21/253, 8.3% [5.3-13%]	26/145, 18% [12-25%]	
I have a steady place to live	347/398, 87% [83-90%]	232/253, 92% [87-95%]	115/145, 79% [72-85%]	
Missing data	25	12	13	
[1] Pearson's Chi-squared test; Wilcoxon rank sum test; Fisher's exact test				

457
458

459   Table 3. Health status

Characteristic	Overall, N = 423	No internal tremors, N = 265	Has internal tremors, N = 158	p-value[1]
	median, IQR	median, IQR	median, IQR	
Euro-QoL visual analogue scale (0-100)	49, 32-61	50, 35-62	40, 30-60	0.007
How bad your long COVID or other symptoms are (0 to 100) on your worst days?	79, 65-86	73, 60-82	80, 73-90	<0.001
Missing data	24	11	13	
[1] Wilcoxon rank sum test				
IQR, interquartile range				

460